Final results of the multicenter randomized phase II PAZOGIST trial evaluating the efficacy of pazopanib (P) plus best supportive care (BSC) vs BSC alone in resistant unresectable metastatic and/or locally advanced gastrointestinal stromal tumors (GIST)

Autor:	Julien Gautier, Emmanuelle Bompas, Philippe A. Cassier, Mathieu Molimard, Aurelie Belleville, Jean-Yves Blay, Maud Toulmonde, François Bertucci, Maria Rios, Claire Cropet, Florence Duffaud, Olivier Bouché, Axel Le Cesne, Antoine Italiano, Olivier Mir, David Pérol, Julien Domont, Antoine Adenis, Nicolas Isambert, Isabelle Ray-Coquard
Rok vydání:	2015
Předmět:	Oncology Cancer Research medicine.medical_specialty Gastrointestinal tract Stromal cell GiST business.industry Sunitinib Locally advanced Imatinib digestive system diseases Surgery Pazopanib chemistry.chemical_compound chemistry Internal medicine Regorafenib medicine business neoplasms medicine.drug
Zdroj:	Journal of Clinical Oncology. 33:10506-10506
ISSN:	1527-7755 0732-183X
DOI:	10.1200/jco.2015.33.15_suppl.10506
Popis:	10506 Background: GIST is the most common mesenchymal neoplasm of the gastrointestinal tract. Imatinib followed by sunitinib then regorafenib is the usual sequence in advanced setting. P is effecti...
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_________::27e89d970c36ff63a24b051cd34206f3 https://doi.org/10.1200/jco.2015.33.15_suppl.10506 Zobrazit plný text záznamu